Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.32 HKD | -2.74% | +6.95% | +17.41% |
Apr. 26 | Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA | MT |
Apr. 24 | Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+17.41% | 1.17B | |
-3.45% | 87.17B | |
+2.76% | 40.1B | |
-16.98% | 31.38B | |
+57.86% | 25.12B | |
-16.24% | 15.59B | |
-9.12% | 12B | |
-42.56% | 11.8B | |
-17.10% | 11.8B | |
+6.89% | 8.81B |
- Stock Market
- Equities
- 2696 Stock
- News Shanghai Henlius Biotech, Inc.
- Correction: Henlius Biotech, Essex Bio-Tech Dose First Patient for Ophthalmic Drug Trial in the US